Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo Controlled, Phase 3 Registration Clinical Trial to Evaluate AntiCovir (Interferon a2b) as a Treatment for COVID-19 in Australia

Next Previous
Search
Trial Profile

A Randomized, Double-Blind, Placebo Controlled, Phase 3 Registration Clinical Trial to Evaluate AntiCovir (Interferon a2b) as a Treatment for COVID-19 in Australia

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 27 Jan 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interferon alpha-2b (Primary)
  • Indications COVID 2019 infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Altum Pharmaceuticals

    • Most Recent Events

    • 21 Jan 2021 According to a BetterLife Pharma media release, company has engaged Equilab International to manage the upcoming clinical trials for its proprietary formulation of Interferon alpha2b (AP-003) in mild to moderate cases of COVID-19.
    • 28 Oct 2020 According to a BetterLife Pharma media release, study participants with mild to moderate COVID-19 will self-identify for potential trial enrollment following COVID-19 testing at testing centers; Trial consent will be obtained virtually and the trial will be conducted via telemedicine from the participants home.
    • 28 Oct 2020 According to a BetterLife Pharma media release, the company is due to start its clinical trials in Australia later this fall.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top